by Staff Writers
San Antonio TX (SPX) Mar 23, 2012
For the past 40 years, radiation has been the most effective method for treating deadly brain tumors called glioblastomas. But, although the targeting technology has been refined, beams of radiation still must pass through healthy brain tissue to reach the tumor, and patients can only tolerate small amounts before developing serious side effects.
A group of researchers at The University of Texas Health Science Center at San Antonio have developed a way to deliver nanoparticle radiation directly to the brain tumor and keep it there.
The method doses the tumor itself with much higher levels of radiation - 20 to 30 times the current dose of radiation therapy to patients - but spares a much greater area of brain tissue.
The study, published in the journal Neuro-Oncology, has been successful enough in laboratory experiments that they're preparing to start a clinical trial at the Cancer Therapy and Research Center, said Andrew Brenner, M.D., Ph.D., the study's corresponding author and a neuro-oncologist at the CTRC who will lead the clinical trial.
"We saw that we could deliver much higher doses of radiation in animal models," Dr. Brenner said. "We were able to give it safely and we were able to completely eradicate tumors."
The radiation comes in the form of an isotope called rhenium-186, which has a short half-life. Once placed inside the tumor, the rhenium emits radiation that only extends out a few millimeters.
But simply putting the rhenium into a brain tumor would not work well without a way to keep it there - the tiny particles would be picked up by the bloodstream and carried away.
That problem was solved by a team led by nuclear medicine physician William T. Phillips, M.D., and biochemist Beth A. Goins, Ph.D., in the Department of Radiology; and Ande Bao, Ph.D., a medical physicist and pharmaceutical chemist in the Department of Otolaryngology, all of the School of Medicine at the UT Health Science Center. They encapsulated the rhenium in miniscule fat molecules, or liposomes, about 100 nanometers across.
"The technology is unique," Dr. Brenner said. "Only we can load the liposomes to these very high radioactivity levels."
The doctors hope to launch the clinical trial by summer.
The Cancer Therapy and Research Center (CTRC)
Hospital and Medical News at InternDaily.com
Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.
Team discovers how bacteria resist a 'Trojan horse' antibiotic
Champaign IL (SPX) Mar 21, 2012
A new study describes how bacteria use a previously unknown means to defeat an antibiotic. The researchers found that the bacteria have modified a common "housekeeping" enzyme in a way that enables the enzyme to recognize and disarm the antibiotic. The study appears in the Proceedings of the National Academy of Sciences. Bacteria often engage in chemical warfare with one another, and ... read more
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2012 - Space Media Network. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement|